Select Publications

Journal articles

Kovačić N; Lukić IK; Grčević D; Katavić V; Croucher P; Marušić A, 2007, 'The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis', Journal of Immunology, 178, pp. 3379 - 3389, http://dx.doi.org/10.4049/jimmunol.178.6.3379

Rabin N; Kyriakou C; Coulton L; Gallagher OM; Buckle C; Benjamin R; Singh N; Glassford J; Otsuki T; Nathwani AC; Croucher PI; Yong KL, 2007, 'A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer', Leukemia, 21, pp. 2181 - 2191, http://dx.doi.org/10.1038/sj.leu.2404814

Locklin RM; Croucher PI; Russell RGG; Edwards CM, 2007, 'Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment', Leukemia, 21, pp. 805 - 812, http://dx.doi.org/10.1038/sj.leu.2404518

Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI, 2007, 'An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma', Cancer Research, 67, pp. 202 - 208, http://dx.doi.org/10.1158/0008-5472.CAN-06-1287

Terpos E; Heath DJ; Rahemtulla A; Zervas K; Chantry A; Anagnostopoulos A; Pouli A; Katodritou E; Verrou E; Vervessou EC; Dimopoulos MA; Croucher PI, 2006, 'Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma', British Journal of Haematology, 135, pp. 688 - 692, http://dx.doi.org/10.1111/j.1365-2141.2006.06356.x

Terpos E; Heath D; Rahemtulla A; Zervas K; Chantry A; Anagnostopoulos A; Pouli A; Katodritou E; Verrou E; Vervessou EC; Dimopoulos MA; Croucher P, 2006, 'Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.', Blood, 108, pp. 506 - 506, http://dx.doi.org/10.1182/blood.v108.11.506.506

Rabin N; Kyriakou C; Benjamin R; Pizzey A; Gallagher O; Singh N; Buckle C; Croucher P; Nathwani A; Yong K, 2006, 'Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Inhibit Osteoclast Activation and Increase Trabecular Bone Area in a Xenogeneic Murine Model of Myeloma.', Blood, 108, pp. 505 - 505, http://dx.doi.org/10.1182/blood.v108.11.505.505

Vanderkerken K; Medicherla S; Coulton L; Van Camp B; Protter A; Higgins L; Menu E; Croucher P, 2006, 'Inhibition of p38α MAPK Reduces Tumor Burden, Prevents the Development of Myeloma Bone Disease, and Increases Survival in the 5T2 and 5T33 Murine Models of Myeloma.', Blood, 108, pp. 3436 - 3436, http://dx.doi.org/10.1182/blood.v108.11.3436.3436

Terpos E; Anagnostopoulos A; Heath D; Kastritis E; Christoulas D; Anagnostopoulos N; Roussou M; Tsionos K; Croucher P; Dimopoulos MA, 2006, 'The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines.', Blood, 108, pp. 3541 - 3541, http://dx.doi.org/10.1182/blood.v108.11.3541.3541

Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K, 2006, 'Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: A study in the 5TMM model', Clinical and Experimental Metastasis, 23, pp. 291 - 300, http://dx.doi.org/10.1007/s10585-006-9038-6

Politou MC; Heath DJ; Rahemtulla A; Szydlo R; Anagnostopoulos A; Dimopoulos MA; Croucher PI; Terpos E, 2006, 'Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation', International Journal of Cancer, 119, pp. 1728 - 1731, http://dx.doi.org/10.1002/ijc.22033

Karadag A; Zhou M; Croucher PI, 2006, 'ADAM-9 (MDC-9/meltrin-γ), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the α vβ5 integrin', Blood, 107, pp. 3271 - 3278, http://dx.doi.org/10.1182/blood-2005-09-3830

Rabin N; Kyriakou C; Pizzey A; Buckle C; Prideaux M; Croucher P; Nathwani A; Yong K, 2006, '663. Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Reverse Osteoclast Activation in a Xenogeneic Murine Model of Multiple Myeloma', Molecular Therapy, 13, pp. S256 - S256, http://dx.doi.org/10.1016/j.ymthe.2006.08.740

Holen I; Cross SS; Neville-Webbe HL; Cross NA; Balasubramanian SP; Croucher PI; Evans CA; Lippitt JM; Coleman RE; Eaton CL, 2005, 'Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - A role in tumour cell survival?', Breast Cancer Research and Treatment, 92, pp. 207 - 215, http://dx.doi.org/10.1007/s10549-005-2419-8

Vanderkerken K; Asosingh K; Willems A; De Raeve H; Couck P; Gorus F; Croucher P; Van Camp B, 2005, 'The 5T2MM murine model of multiple myeloma: maintenance and analysis.', Methods in molecular medicine, 113, pp. 191 - 205

Kartsogiannis V; Ly C; Zhou H; Gallagher O; Buckle C; De Leenheer E; Vanderkerken K; Ng KW; Martin T; gillespie M; Croucher P, 2005, 'Expression of RANKL, OPG, PTHrP and OCIL in multiple myeloma are influenced by the tumor cells` proximity to bone', Journal of Bone and Mineral Research, 20, pp. S211 - S211

Croucher PI, 2004, 'The RANKL system and the development of tumor-induced bone disease: Lessons from pre-clinical models', Journal of Musculoskeletal Neuronal Interactions, 4, pp. 285 - 292

Eaton CL; Wells JM; Holen I; Croucher PI; Hamdy FC, 2004, 'Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer', Prostate, 59, pp. 304 - 310, http://dx.doi.org/10.1002/pros.20016

De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI, 2004, 'Evidence of a role for RANKL in the development of myeloma bone disease', Current Opinion in Pharmacology, 4, pp. 340 - 346, http://dx.doi.org/10.1016/j.coph.2004.03.011

Van Valckenborgh E; Croucher PI; De Raeve H; Carron C; De Leenheer E; Blacher S; Devy L; Noël A; De Bruyne E; Asosingh K; Van Riet I; Van Camp B; Vanderkerken K, 2004, 'Multifunctional role of matrix metalloproteinases in multiple myeloma: A study in the 5T2MM mouse model', American Journal of Pathology, 165, pp. 869 - 878, http://dx.doi.org/10.1016/S0002-9440(10)63349-4

Menu E; Asosingh K; Van Riet I; Croucher P; Van Camp B; Vanderkerken K, 2004, 'Myeloma cells (5TMM) and their interactions with the marrow microenvironment', Blood Cells, Molecules, and Diseases, 33, pp. 111 - 119, http://dx.doi.org/10.1016/j.bcmd.2004.04.012

Vanderkerken K; Asosingh K; Croucher P; Van Camp B, 2003, 'Multiple myeloma biology: Lessons from the 5TMM models', Immunological Reviews, 194, pp. 196 - 206, http://dx.doi.org/10.1034/j.1600-065X.2003.00035.x

Shipman CM; Croucher PI, 2003, 'Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells', Cancer Research, 63, pp. 912 - 916

Croucher PI; De Raeve H; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K, 2003, 'Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival', Journal of Bone and Mineral Research, 18, pp. 482 - 492, http://dx.doi.org/10.1359/jbmr.2003.18.3.482

Vanderkerken K; De Leenheer E; Shipman C; Asosingh K; Willems A; Van Camp B; Croucher P, 2003, 'Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma', Cancer Research, 63, pp. 287 - 289

Ashcroft AJ; Cruickshank SM; Croucher PI; Perry MJ; Rollinson S; Lippitt JM; Child JA; Dunstan C; Felsburg PJ; Morgan GJ; Carding SR, 2003, 'Colonic Dendritic Cells, Intestinal Inflammation, and T Cell-Mediated Bone Destruction Are Modulated by Recombinant Osteoprotegerin', Immunity, 19, pp. 849 - 861, http://dx.doi.org/10.1016/S1074-7613(03)00326-1

Croucher P; Jagdev S; Coleman R, 2003, 'The anti-tumor potential of zoledronic acid', Breast, 12, http://dx.doi.org/10.1016/S0960-9776(03)80161-3

Holen I; Croucher PI; Hamdy FC; Eaton CL, 2002, 'Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells', Cancer Research, 62, pp. 1619 - 1623

Holen I; Eaton C; Hamdy F; Croucher P, 2002, 'Production of osteoprotegerin by prostate cancer cells suppresses trial induced apoptosis', European Urology Supplements, 1, pp. 54 - 54, http://dx.doi.org/10.1016/s1569-9056(02)80203-2

Wells J; Holen I; Croucher P; Hamdy F; Eaton C, 2002, 'Serum osteoprotegerin levels are increased in hormone resistant prostate cancer patients', European Urology Supplements, 1, pp. 159 - 159, http://dx.doi.org/10.1016/s1569-9056(02)80621-2

Croucher PI; Shipman CM; Lippitt J; Perry M; Asosingh K; Hijzen A; Brabbs AC; Van Beek EJR; Holen I; Skerry TM; Dunstan CR; Russell GR; Van Camp B; Vanderkerken K, 2001, 'Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma', Blood, 98, pp. 3534 - 3540, http://dx.doi.org/10.1182/blood.V98.13.3534

Holen I; Drury NL; Hargreaves PG; Croucher PI, 2001, 'Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells', British Journal of Haematology, 114, pp. 414 - 421, http://dx.doi.org/10.1046/j.1365-2141.2001.02963.x

Salomo M; Gimsing P; Shipman CM; Croucher PI, 2001, 'Bisphosphonates and in vivo models of multiple myeloma [3] (multiple letters)', British Journal of Haematology, 113, pp. 841 - 842, http://dx.doi.org/10.1046/j.1365-2141.2001.02804-3.x

Russell G; Mueller G; Shipman C; Croucher P, 2001, 'Clinical disorders of bone resorption.', Novartis Foundation symposium, 232

Asosingh K; De Raeve H; Croucher P; Goes E; Van Riet I; Van Camp B; Vanderkerken K, 2001, 'In vivo homing and differentiation characteristics of mature (CD45) and immature (CD45+) 5T multiple myeloma cells', Experimental Hematology, 29, pp. 77 - 84, http://dx.doi.org/10.1016/S0301-472X(00)00625-1

Zhou M; Graham R; Russell G; Croucher PI, 2001, 'MDC-9 (adam-9/meltrin γ) functions as an adhesion molecule by binding the αvβ5 integrin', Biochemical and Biophysical Research Communications, 280, pp. 574 - 580, http://dx.doi.org/10.1006/bbrc.2000.4155

Jagdev SP; Coleman RE; Shipman CM; Rostami-H. A; Croucher PI, 2001, 'The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel', British Journal of Cancer, 84, pp. 1126 - 1134, http://dx.doi.org/10.1054/bjoc.2001.1727

Shipman CM; Croucher PI; Vanderkerken K, 2001, 'Reply to salomo and gimsing', British Journal of Haematology, 113, pp. 842 - 842, http://dx.doi.org/10.1046/j.1365-2141.2001.02804-4.x

Jagdev SP; Croucher PI; Coleman RE, 2001, 'The effects of intravenous bisphosphonate treatment on the bone microenvironment in patients with breast cancer and bone metastases', European Journal of Cancer, 37, pp. S129 - S129, http://dx.doi.org/10.1016/s0959-8049(01)80965-5

Shipman CM; Vanderkerken K; Rogers MJ; Lippitt JM; Asosingh K; Hughes DE; Van Camp B; Russell RGG; Croucher PI, 2000, 'The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma', British Journal of Haematology, 111, pp. 283 - 286, http://dx.doi.org/10.1046/j.1365-2141.2000.02310.x

Karadag A; Oyajobi BO; Apperley JF; Graham R; Russell G; Croucher PI, 2000, 'Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts', British Journal of Haematology, 108, pp. 383 - 390, http://dx.doi.org/10.1046/j.1365-2141.2000.01845.x

Karadag A; Scutt AM; Croucher PI, 2000, 'Human myeloma cells promote the recruitment of osteoblast precursors: Mediation by interleukin-6 and soluble interleukin-6 receptor', Journal of Bone and Mineral Research, 15, pp. 1935 - 1943, http://dx.doi.org/10.1359/jbmr.2000.15.10.1935

Apperley JF; Croucher PI, 1999, 'Bisphosphonates in multiple myeloma', Pathologie Biologie, 47, pp. 178 - 181

Sati HIA; Greaves M; Apperley JF; Russell RGG; Croucher PI, 1999, 'Expression of interleukin-1β and tumour necrosis factor-α in plasma cells from patients with multiple myeloma', British Journal of Haematology, 104, pp. 350 - 357, http://dx.doi.org/10.1046/j.1365-2141.1999.01193.x

Croucher PI; Wang F; Hargreaves PG, 1999, 'Interleukin-6 Receptor (IL-6R) Shedding: A Role for Members of the ADAM Family', Biochemical Society Transactions, 27, pp. A23 - A23, http://dx.doi.org/10.1042/bst027a023a

Croucher PI; Apperley JF, 1998, 'Bone disease in multiple myeloma', British Journal of Haematology, 103, pp. 902 - 910, http://dx.doi.org/10.1046/j.1365-2141.1998.01082.x

Shipman CM; Croucher PI; Russell RGG; Helfrich MH; Rogers MJ, 1998, 'The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway', Cancer Research, 58, pp. 5294 - 5297

Hargreaves PG; Wang F; Antcliff J; Murphy G; Lawry J; Russell RGG; Croucher PI, 1998, 'Human myeloma cells shed the interleukin-6 receptor: Inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor', British Journal of Haematology, 101, pp. 694 - 702, http://dx.doi.org/10.1046/j.1365-2141.1998.00754.x

Sati HIA; Apperley JF; Greaves M; Lawry J; Gooding R; Russell RGG; Croucher PI, 1998, 'Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance', British Journal of Haematology, 101, pp. 287 - 295, http://dx.doi.org/10.1046/j.1365-2141.1998.00687.x

Shipman CM; Rogers MJ; Apperley JF; Russell RGG; Croucher PI, 1998, 'Anti-tumour activity of bisphosphonates in human myeloma cells', Leukemia and Lymphoma, 32, pp. 129 - 138, http://dx.doi.org/10.3109/10428199809059253


Back to profile page